Drug
Deferasirox clinical trials
Also written ICL670, Exjade and osveral.
- studies test it
- 83
- open now
- 2
- in phase 3
- 10
- first study started
- 2002
Keep track of what changes. Save the Deferasirox studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
83 studies that test it; most in 2007 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 13 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 6 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 45
- Phase 3
- 10
- Phase 4
- 18
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 51 · Other 32
Novartis Pharmaceuticals (45) · Novartis (5) · University Hospital, Grenoble (1) · RESnTEC, Institute of Research (1) · Boston Children's Hospital (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · DisperSol Technologies, LLC (1)
Often tested with
Tested in the same studies.
Deferoxamine (6) · Azacitidine (4) · Deferiprone (2) · Iron sucrose (1) · Isoflurophate (1) · Cholecalciferol (1) · Vitamin D (1)
Studies
Open first, then newest update. How each study uses Deferasirox is read from its arms, and is right about nine times in ten.
Testing it · 83
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingPhase 2Inova Health Care ServicesNCT07023666Written as Deferasirox
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell TransplantationRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT06784336Written as Iron chelation
- Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA AgentsCompletedPhase 2University Hospital, GrenobleNCT03387475Written as Deferasirox
- Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedPhase 2Novartis PharmaceuticalsNCT03203850Written as Deferasirox FCT
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedPhase 2Novartis PharmaceuticalsNCT02435212Written as Deferasirox granule formulation
- Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNot applicableRESnTEC, Institute of ResearchNCT06468423Written as Deferasirox (DFX)
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnPhase 2Haukeland University HospitalNCT01892644Written as Deferasirox
- Pilot Study for Patients With Poor Response to DeferasiroxCompletedPhase 4Boston Children's HospitalNCT00749515Written as Deferasirox
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) StudyCompletedPhase 2Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT00419770Written as deferasirox
- Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell DiseaseCompletedPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05392101Written as Deferasirox 360 MG
- Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSTerminatedPhase 2Fondazione Italiana Sindromi Mielodisplastiche-ETSNCT03920657Written as Deferasirox
- Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to ChelationCompletedPhase 2DisperSol Technologies, LLCNCT03637556Written as DST-0509
- Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible TabletCompletedPhase 2Novartis PharmaceuticalsNCT02993224Written as Deferasirox film coated tablet (FCT)
- Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedPhase 2Novartis PharmaceuticalsNCT00110266Written as Deferasirox
- Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedPhase 2Elliott VichinskyNCT00901199Written as Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
- Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedPhase 2Novartis PharmaceuticalsNCT01254227Written as Deferasirox and Deferoxamine
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedPhase 4Novartis PharmaceuticalsNCT00845871Written as deferasirox:
- Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedPhase 2Novartis PharmaceuticalsNCT00631163Written as Deferasirox (ICL670)
- Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedPhase 4Novartis PharmaceuticalsNCT00117507Written as Deferasirox
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedPhase 2NovartisNCT00447694Written as Deferasirox
See all 83 studies that test Deferasirox →
Given in every arm · 3 — Deferasirox is usual care beside what is tested
- Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia PatientsCompletedPhase 2Ain Shams UniversityNCT07863791Written as Deferasirox
- Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia PatientsStatus unknownNot applicableKevin H.M. Kuo, MD, MSc, FRCPCNCT02474420Written as Deferasirox
- Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedPhase 2Novartis PharmaceuticalsNCT00110617Written as Deferasirox (ICL670)
As the comparator · 2 — what is tested is compared with Deferasirox
Codes
What other systems call Deferasirox · ClinicalTrials.gg INT006763
- MeSH (NLM) D000077588DeferasiroxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V8G4MOF2V9DEFERASIROXConfirmed FDA, NLM, Wikidata
- RxNorm 614373Confirmed FDA, Wikidata
- Wikidata Q5251502deferasiroxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48384DeferasiroxConfirmed FDA, Wikidata
- DrugBank DB01609One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077588 | Deferasirox | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V8G4MOF2V9 | DEFERASIROX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 614373 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5251502 | deferasirox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48384 | Deferasirox | Confirmed FDA, Wikidata |
| DrugBank | DB01609 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.